Research Article Details
| Article ID: | A22049 |
| PMID: | 24850609 |
| Source: | Georgian Med News |
| Title: | [Effect of gene polymorphism of PPARgamma2 regulatory proteins on the metabolic syndrome in children with nonalcoholic fatty liver disease and obesity]. |
| Abstract: | The aim of this study was to investigate the influence of single nucleotide polymorphism Pro12Ala of PPARγ2 gene in phenotypical manifestations, carbohydrate and lipid metabolism, blood pressure (BP) and tumor necrosis factor alpha (TNF-α) in children with exogenous constitutional obesity (ECO) and nonalcoholic fatty liver disease (NAFLD). 67 children aged from 7 to 17 years were examined; among them 34 patients were diagnosed with NAFLD and 33 children with ECO. The algorithm of examination included assessment of anthropometric parameters, blood lipid profile, glucose indicators and immunoreactive insulin (IRI) on an empty stomach, the calculation of the HOMA-IR index, genetic methods of examination. The study of Pro12Ala polymorphism of PPARγ2 gene showed that patients with NAFLD demonstrated the highest percentage in the frequency of the "wild genotype" Pro/Pro (88,2%) and significantly lower prevalence rate in frequency of allele Ala (11,8%). The presence of the polymorphic allele Ala was associated with lower levels of IRI, HOMA-IR index, a significant reduction of virtually all components of lipid metabolism, systolic blood pressure and pro-inflammatory cytokine TNF-α. Children with genotype X/Ala have greater body weight and higher BMI as compared with homozygous carriers of Pro allele. The detected changes allow us to recommend the use of genetic screening to identify single nucleotide polymorphism Pro12Ala of PPARγ2 gene in obese children in order to determine the degree of risk of metabolic disorders development and implement the preventive measures in a timely manner. |
| DOI: |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| S02 | Enhance lipid metabolism | triglyceride-lowering; lipid tolerance; lipid metabolism | 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitor; Decreases intestinal cholesterol absorption; FXR agonist; ACC inhibitor; FAS inhibitor; DGAT2 inhibitor; SCD-1 inhibitor | Atorvastatin; Ezetimibe; Obeticholic Acid; GS-9674; GS-0976; TVB-2640; IONIS-DGAT2rx; Aramchol; | Details |
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |